Bracco adds to radiopharmaceutical portfolio

Italian contrast developer Bracco continues to expand its portfolio of nuclear medicine products. The company this week announced that it has acquired new radiopharmaceutical products and intellectual property from Resolution Pharmaceutical, a Canadian developer of products for diagnosing and treating tumors.

Bracco executives said the purchase is in line with other recent moves to build the company's portfolio, such as a recently formed alliance with Dyax Pharmaceutical of Cambridge, MA.

By staff writers
December 19, 2000

Related Reading

Bracco allies with pharmaceutical developer Dyax, November 6, 2000

Copyright © 2000

Page 1 of 3597
Next Page